噻托溴铵治疗慢性阻塞性肺疾病的临床疗效和安全性

The clinical efficacy and safety of tiotropium bromide in the treatment of chronic obstructive pulmonary disease

目的：探讨噻托溴铵粉雾剂治疗慢性阻塞性肺疾病（COPD）的临床疗效和安全性。方法选取青岛市黄岛区中医医院2013年1月至2013年12月确诊为COPD的102例患者作为研究对象，将其随机分为治疗组与对照组，对照组患者施行常规药物治疗，治疗组患者在常规药物治疗基础上加用噻托溴铵粉雾剂治疗，比较两组患者治疗4周后及8周后肺功能指标、血气分析指标、6 min 步行距离（6MWD）、SGRQ、转化生长因子β1（TGF-β1）阳性率及不良反应例数。结果治疗组治疗后4周及8周FEV1、FVC高于治疗前，差异具有统计学意义（P〈0.05）；治疗组患者6MWD在治疗4周后及8周后高于治疗前，差异具有统计学意义（P〈0.05）；治疗组患者SGRQ评分在治疗4周后及8周后低于治疗前，差异具有统计学意义（P〈0.05）；治疗组患者PaCO2、TGF-β1阳性率在治疗4周后及8周后低于治疗前，PaO2高于治疗前，差异具有统计学意义（P〈0.05），且与对照组相比，差异具有统计学意义（P〈0.05）。结论噻托溴铵粉雾剂治疗COPD疗效确切，安全可靠，值得临床推广。

ObjectiveTo investigate the Tiotropium Bromide Powder for Inhalation in treatment of chronic obstructive pulmonary disease （COPD） clinical efficacy and safety.Methods102 patients with COPD were randomly divided into treatment group and control group, the control group were treated with routine drug therapy, the patients in the treatment group plus tiotropium bromide powder spray treatment with thiabendazole in the conventional drug treatment on the basis of comparison of two groups of patients for the treatment of pulmonary function, blood gas analysis after 4 weeks and 8 weeks after the index, 6 min walking distance, SGRQ, transforming growth factor beta 1 positive rate and the number of cases of adverse reactions. ResultsAfter treatment, 4 weeks and 8 weeks of FEV1, FVC was higher than that before treatment, with significant difference （P〈0.05）; the patients in the treatment group were higher than that in 6MWD treatment after 4 weeks of treatment and after 8 weeks ago, with statistically significant difference （P〈0.05）; the patients in the treatment group the SGRQ score after treatment for 4 weeks and 8 weeks after less than before treatment, with significant difference （P〈0.05）; the patients in the treatment group were PaCO2, TGF- beta 1 positive rate in the treatment of 4 weeks and 8 weeks after lower than that before treatment, PaO2 was higher than that before treatment, with significant difference （P〈0.05）, and compared with the control group, the differences were statistically significant （P〈0.05）.ConclusionTiotropium Bromide Powder for Inhalation treatment of COPD is effective, safe and reliable, worthy of clinical application..